New ADC treatment options for patients in need

Adcendo ApS is a Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers

What are ADCs?

Antibody-drug conjugates (ADCs) represent an emerging drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules. 10+ ADCs are now in routine clinical use for cancer patients, with many more novel ADC assets currently investigated in clinical studies in solid tumors and hematologic malignancies

The uPARAP receptor

The uPARAP receptor was originally identified and cloned by the scientific founders of Adcendo, who have worked for more than 20 years on elucidating the role and function of the receptor in collagen turnover and cancer development & metastasis

Our name, Adcendo, reflects our aim to
develop ADCs targeting endocytic receptors overexpressed on cancer cells or on specific cells of the tumor microenvironment

About Adcendo

Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published proof-of-concept for uPARAP-directed ADCs, where a first-generation, anti-uPARAP ADC was shown to effectively mediate a curative outcome in a CDX model. Ensuring that these findings were investigated further by creating a spin-out company for this purpose, was a natural next step

Join our ambitious team

Please reach out to us if you are interested in joining our international team of highly experienced cancer researchers and drug developers. Do you have relevant expertise and are attracted by a science-, value- and performance driven work environment? Then check out the careers section

Our investors

In April 2021, Adcendo ApS closed our series A investment round at 51m EUR, though an international syndicate of leading life science and biotech investors